Aureum Therapeutics Announces Successful Prevention of Recurrent Miscarriage using NomiCell™ Stem Cells in Preclinical Studies
Publication in Peer-Reviewed Journal Details Mechanisms of Miscarriage and Provides Potential Solution SAN DIEGO, July 9, 2026 /PRNewswire/ -- Aureum Therapeutics, a clinical-stage biotechnology company dedicated to developing immunology-based treatments for recurrent miscarriage and...
Publication in Peer-Reviewed Journal Details Mechanisms of Miscarriage and Provides Potential Solution SAN DIEGO, July 9, 2026 /PRNewswire/ -- Aureum Therapeutics, a clinical-stage biotechnology company dedicated to developing immunology-based treatments for recurrent miscarriage and...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.